HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gallo, J. I. Articles by Duran, C. M. G. Search for Related Content PubMed PubMed Citation Articles by Gallo, J. I. Articles by Duran, C. M. G.

Ann Thorac Surg 1981;31:444-449
© 1981 The Society of Thoracic Surgeons

---

Articles

Heart Valve Replacement with the Hancock Bioprosthesis: A 6-Year Review

Department of Cardiovascular Surgery, Centro Médico Nacional "Marqués de Valdecilla", Universidad de Santander, Santander, Spain

Accepted for publication September 29, 1980.

^* Address reprint requests to Dr. Gallo, Department Cirugia Cardiovascular, Centro Médico Nacional "Marqués de Valdecilla", Santander, Spain

All patients who had a mitral or aortic Hancock valve replacement between June, 1974, and June, 1979, were reviewed. A total of 734 bioprostheses were implanted in 632 patients: 291 had mitral (MVR), 239 had aortic (AVR), and 102 had both mitral and aortic valve replacement (MVR + AVR). In 228 patients, an associated surgical procedure was necessary. It involved conservative valve operation in 205 of them. The hospital mortality was 9.6% (28) for MVR (11.5% with associated operation), 4.6% (11) for AVR (8.7% with associated operation), and 13.7% (14) for MVR + AVR (13.0% with associated operation).

The follow-up period was between 1 and 6 years with a total follow-up of 934.6, 714.6, and 288.3 patient-years for MVR, AVR, and MVR + AVR, respectively. The late mortality was 0.96% (9), 1.53% (11), and 2.08% (6) per patient-year for MVR, AVR, and MVR + AVR, respectively. The thromboembolic rate was 1.49%, 0.14%, and 2.08% per patient-year for MVR, AVR, and MVR + AVR, respectively. There were twelve valve failures (six were due to rupture; four, thrombosis; one, insufficiency because of intrinsic failure; and one, stenosis without evident cause at reoperation). This represents a failure rate of 0.53%, 0.13%, and 2.08% per patient-year for MVR, AVR, and MVR + AVR, respectively. These results encourage us to continue our routine use of the glutaraldehyde xenografts as the safest valve substitute at present.

This article has been cited by other articles:

				K.-T. Tsai, P. J. Lin, C.-H. Chang, J.-J. Chu, J.-P. Chang, C.-L. Kao, and M.-J. Hsieh Surgical management of thrombotic disc valve Ann. Thorac. Surg., January 1, 1993; 55(1): 98 - 101. [Abstract] [PDF]

				G. J. Kontos Jr, H. V. Schaff, T. A. Orszulak, F. J. Puga, J. R. Pluth, and G. K. Danielson Thrombotic obstruction of disc valves: Clinical recognition and surgical management Ann. Thorac. Surg., July 1, 1989; 48(1): 60 - 65. [Abstract] [PDF]

				L. H. Edmunds Jr. Thrombotic and Bleeding Complications of Prosthetic Heart Valves Ann. Thorac. Surg., October 1, 1987; 44(4): 430 - 445. [Abstract] [PDF]

				M. P. Brais, J. P. Bedard, W. Goldstein, A. Koshal, and W. J. Keon Ionescu-Shiley Pericardial Xenografts: Follow-up of Up to 6 Years Ann. Thorac. Surg., February 1, 1985; 39(2): 105 - 111. [Abstract] [PDF]

				V. Gallucci, U. Bortolotti, A. Milano, C. Valfre, A. Mazzucco, and G. Thiene Isolated Mitral Valve Replacement with the Hancock Bioprosthesis: A 13-Year Appraisal Ann. Thorac. Surg., December 1, 1984; 38(6): 571 - 578. [Abstract] [PDF]

				S. Gabbay, U. Bortolotti, G. Cipolletti, F. Wasserman, R. W. M. Frater, and S. M. Factor The Meadox Unicusp Pericardial Bioprosthetic Heart Valve: New Concept Ann. Thorac. Surg., June 1, 1984; 37(6): 448 - 456. [Abstract] [PDF]

				A. Starr and G. L. Grunkemeier Selection of a Prosthetic Heart Valve JAMA, April 6, 1984; 251(13): 1739 - 1742. [Abstract] [PDF]

				H. Bolooki, S. Mallon, G. A. Kaiser, R. J. Thurer, and J. Kieval Failure of Hancock Xenograft Valve: Importance of Valve Position (4- to 9-Year Follow-up) Ann. Thorac. Surg., September 1, 1983; 36(3): 246 - 252. [Abstract] [PDF]

				J. M. Craver, E. L. Jones, P. McKeown, D. K. Bone, C. R. Hatcher Jr., and M. Kandrach Porcine Cardiac Xenograft Valves: Analysis of Survival, Valve Failure, and Explantation Ann. Thorac. Surg., July 1, 1982; 34(1): 16 - 21. [Abstract] [PDF]